当前位置：网站首页  >> 外文  >> 查看详情

China drugmaker begins trial production of AstraZeneca COVID-19 vaccine

时间：2021-02-03 14:07:50来源： 德国新闻网

A Shenzhen-based drugmaker on Tuesday began trial production of a COVID-19 vaccine from multinational pharmaceutical company AstraZeneca.

Shenzhen Kangtai Biological Products Co. Ltd. announced that it has built a production workshop for the adenovirus vector vaccine developed by AstraZeneca and the University of Oxford, which won the approval for emergency use in the United Kingdom on Dec. 30.

The facility, with a floor area of 2,200 square meters, has an annual production capacity of 400 million doses.

The Shenzhen drugmaker signed a deal with AstraZeneca in August 2020 to introduce the latter's COVID-19 vaccine into China for which it is seeking clinical registration.

The company itself developed an inactivated coronavirus vaccine and is planning to launch phase 3 trials.

最新文章

上一篇：China urges U.S. to cease meddling in its internal affairs

网站首页

下一篇：U.S. Senate confirms Pete Buttigieg as transportation secretary



本类推荐

本类排行

广告推荐

关于我们广告服务版权声明联系我们

德国新闻网版权所有 网站备案号：